# Sino Biopharmaceutical

> Sino Biopharmaceutical is a VC fund backing Biotechnology and Health Care. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Wan Chai, Hong Kong
- Total investments: 15
- Last investment: Jul 2026
- Lead investor: 53%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/sino-biopharmaceutical-limited/
- X (Twitter): https://twitter.com/SinoBiopharm
- Website: http://www.sinobiopharm.com/
- Facebook: https://www.facebook.com/Sino-Biopharmaceutical-Limited-526673520856616/

Sino Biopharmaceutical is a VC fund in Wan Chai focused on Biotechnology and Health Care. Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemicalmedicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.

## Contacts

5 contacts available for Sino Biopharmaceutical. Shizune tracks 3 team members at Sino Biopharmaceutical. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/sino-biopharmaceutical?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series B | $91M–$110M |
| Series C | $42M–$736M |
| Series D | $27M–$400M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 8 | 53% |
| Health Care | 7 | 47% |
| Medical | 5 | 33% |
| Biopharma | 4 | 27% |
| Manufacturing | 4 | 27% |

15 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series D | 3 | 20% |
| Series B | 2 | 13% |
| Series C | 2 | 13% |
| Venture - Series Unknown | 2 | 13% |
| Seed | 1 | 7% |

10 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 9 | 60% |
| United States | 3 | 20% |
| Israel | 1 | 7% |
| Taiwan | 1 | 7% |
| Singapore | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Hsin Tse | Executive Director and VP | 2 | https://shizune.co/investors/profile/hsin-tse |
| Ping Tse | Founder & Sr. Vice Chairman | 0 | https://shizune.co/investors/profile/ping-tse |
| Yi Li | President & CEO | 0 | https://shizune.co/investors/profile/yi-li-aab3 |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TranscEngram | TranscEngram is an AI research and technology company focused on advancing artificial intelligence. |  | Angel | Jul 05, 2026 | https://transcengram.com/ |
| AI² Robotics | AI² Robotics is an embodied intelligent robot company that offers research and development of general intelligent embodied terminals. | $735.9M | Series C | Jun 29, 2026 | https://ai2robotics.com/ |
| Sanegene Bio | Sanegene Bio is currently operating in stealth mode. | $110M | Series B | Dec 08, 2025 |  |
| Phrontline Biopharma | Phrontline Biopharma specializes in the development of ADC to address unmet medical needs in the field of oncology. | $60M | Seed | Nov 21, 2025 | https://phrontlinebio.com/ |
| PaiLin Biotech | PaiLin Biotech is a specialized blood product provider focused on the production, collection, storage, and sales of high-quality single-donor plasma. | $534.4M | Post-IPO Equity | Jun 11, 2025 |  |
| LaNova Medicines | LaNova Medicines is a clinical-stage innovative drug research and development company. The company focuses on the unmet therapeutic needs in the field of tumor immunity and tumor microenvironment and focuses on the research and development of "world's first" and "best-in-class" potential bio-innovative drugs. | $42.2M | Series C | Oct 18, 2024 | https://www.lanovamedicines.com/ |
| HanchorBio | HanchorBio is a Biotechnology Research firm that is working to revolutionize the treatment of people with cancer. | $20M | Series A | Aug 25, 2022 | https://hanchorbio.com/ |
| Generon (Shanghai) Corporation | Generon (Shanghai) Corporation Ltd. is an integrated biotech company developing therapeutic biologics for patients world-wide. Their research & development center is located in Zhang Jiang High-Tech Park, Shanghai, China. their cGMP drug manufacturing facility is located in Economic-Technological Development Area, Beijing, China. Theirmission is “Innovating for Life” to develop innovative therapeutic biologics for global patients with unmet medical needs. They employ their proprietary, cutting-edge technology platforms to discover, develop and manufacture biologic therapeutics. They are focused on “best-in-class” and “first-in-class” recombinant therapeutic proteins to treat cancer, autoimmune and inflammatory diseases. They follow international quality standards for their product development and adhere to regulatory requirements of the CFDA, FDA and EMA. “Innovation and quality” are the soul of Generon in the generation of scientific data and in the processes of drug discovery, development and manufacturing. | $70M | Venture - Series Unknown | Jun 02, 2022 | http://www.generonbiomed.com/en/ |
| Evive Biotech | Evive Biotech develops biological therapies for oncology and inflammatory disorders. The company uses proprietary technology platforms to advance drug candidates. It also manages drug development, regulatory compliance, and commercial-scale manufacturing for biologics. | $70M | Venture - Series Unknown | Jun 02, 2022 | https://www.evivebiotech.com/ |
| Medlinker | Medical Alliance is a post of physician social service platform. Users are certified doctors working in the Medical Alliance, they can share knowledge, experience and insights with the other industry elite, to continue to provide high quality content for each other. Application provides a medical quiz, map that case, the anonymous social circlesand doctors and other functions, is committed to helping physicians groups, more convenient access to high-quality information from the industry | $514M | Series E | Dec 12, 2021 | http://medlinker.com/ |

10 of 15 investments shown.

## Co-investors
- [Lake Bleu Capital](https://shizune.co/investors/profile/lake-bleu-capital) — VC Fund, 2 deals together
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together
- [Shenzhen Capital Group](https://shizune.co/investors/profile/shenzhen-capital-group) — VC Fund, 2 deals together
- [Vivo Capital](https://shizune.co/investors/profile/vivo-capital) — VC Fund, 2 deals together
- [Yifan Pharmaceutical](https://shizune.co/investors/profile/yifan-pharmaceutical) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Sigma Partners](https://shizune.co/investors/profile/sigma-partners) — VC Fund
- [EDBI](https://shizune.co/investors/profile/edbi) — VC Fund
- [Trifecta Capital Advisors](https://shizune.co/investors/profile/trifecta-capital-advisors) — VC Fund

### Similar country
- [National Development Fund of Taiwan Government](https://shizune.co/investors/profile/national-development-fund-of-taiwan-government) — VC Fund
- [Darwin Venture Management](https://shizune.co/investors/profile/darwin-venture-management) — VC Fund
- [AVA Angels](https://shizune.co/investors/profile/ava-angels) — VC Fund

## Featured in investor lists
- [Health Care VC Funds in Taiwan](https://shizune.co/investors/health-care-vc-funds-taiwan)
- [Enterprise VC Funds in Taiwan](https://shizune.co/investors/enterprise-vc-funds-taiwan)

## FAQ

### What does Sino Biopharmaceutical invest in?

Sino Biopharmaceutical invests primarily in Biotechnology, Health Care and Medical startups, most often at Series D and Series B stage. Most of the 15 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Sino Biopharmaceutical's check size?

Sino Biopharmaceutical typically joins rounds of $91M–$110M at Series B, $42M–$736M at Series C and $27M–$400M at Series D. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Sino Biopharmaceutical participates in.

### How do I contact Sino Biopharmaceutical?

Public channels for Sino Biopharmaceutical include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Sino Biopharmaceutical?

The team at Sino Biopharmaceutical includes Hsin Tse (Executive Director and VP), Ping Tse (Founder & Sr. Vice Chairman) and Yi Li (President & CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co